aTyr Pharma (LIFE)

Add to Watchlists
Create an Alert
3.45 -0.28  -7.38% NASDAQ Feb 23, 13:59 Delayed 2m USD

aTyr Pharma Research and Development Expense (Quarterly):

10.40M for Sept. 30, 2016
View 4,000+ financial data types
View Full Chart

aTyr Pharma Research and Development Expense (Quarterly) Chart

Export Data
Save Image
Print Image

aTyr Pharma Historical Research and Development Expense (Quarterly) Data

View and export this data going back to 2014. Start your Free Trial
Export Data Date Range:
Data for this Date Range  
Sept. 30, 2016 10.40M
June 30, 2016 11.31M
March 31, 2016 12.00M
Dec. 31, 2015 12.67M
Sept. 30, 2015 7.739M
June 30, 2015 7.502M
March 31, 2015 6.593M
Dec. 31, 2014 4.341M
Sept. 30, 2014 4.41M
June 30, 2014 3.638M
March 31, 2014 4.388M

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

About R&D Expense

R&D expenses are a line item from many companies' income statements.

R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More


LIFE Research and Development Expense (Quarterly) Benchmarks

CoLucid Pharmaceuticals 10.51M
Proteon Therapeutics 4.842M
Biocryst Pharmaceuticals 14.10M

LIFE Research and Development Expense (Quarterly) Range, Past 5 Years

Minimum 3.638M Jun 2014
Maximum 12.67M Dec 2015
Average 7.726M

LIFE Research and Development Expense (Quarterly) Excel Add-In Codes

  • Metric Code: r_and_d_expense
  • Latest data point: =YCP("LIFE", "r_and_d_expense")
  • Last 5 data points: =YCS("LIFE", "r_and_d_expense", -4)

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.


You've hit the 10 page limit on YCharts.

Experience the power of YCharts.
Start your Free 7-Day Trial.

Start My Free Trial No credit card required.

Already a subscriber? Sign in.


Start your free 7-Day Trial.

{{}} No credit card required.

Already a subscriber? Sign in.